Abstract | OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of rimegepant for treatment of migraine. DATA SOURCES: A comprehensive PubMed and Cochrane search (1985 to May 2020) was performed utilizing the keywords rimegepant, Nurtec, orally disintegrating tablet, migraine, migraine headache, migraine disorder, calcitonin gene-related peptide, and calcitonin gene-related peptide antagonist. Additional data were obtained from the references of identified articles, manufacturer's product labeling and website, ClinicalTrials.gov, and governmental sources. STUDY SELECTION AND DATA EXTRACTION: All English-language trials evaluating oral rimegepant were included for this review. DATA SYNTHESIS:
Rimegepant orally disintegrating tablet (ODT) is Food and Drug Administration approved for the treatment of migraine. According to data from 3 phase 3 randomized controlled trials, rimegepant has been shown to significantly improve freedom from pain at 2 hours after the dose and freedom from the most bothersome symptom 2 hours postdose. Additional outcomes improved include freedom from photophobia and phonophobia at 2 hours postdose and pain relief 2 hours after the dose. Adverse effects of rimegepant include nausea, urinary tract infection, and dizziness. RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE: CONCLUSION:
Rimegepant ODT is an efficacious migraine treatment option with a novel mechanism of action, convenient dosage form, and limited adverse effect profile.
|
Authors | Alicia Potter DeFalco, Rachel Lazim, Nathan E Cope |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 55
Issue 5
Pg. 650-657
(05 2021)
ISSN: 1542-6270 [Electronic] United States |
PMID | 32909437
(Publication Type: Journal Article)
|
Chemical References |
- Calcitonin Gene-Related Peptide Receptor Antagonists
- Piperidines
- Pyridines
- Tablets
- rimegepant sulfate
- Calcitonin Gene-Related Peptide
|
Topics |
- Acute Disease
- Administration, Oral
- Calcitonin Gene-Related Peptide
(antagonists & inhibitors)
- Calcitonin Gene-Related Peptide Receptor Antagonists
(pharmacokinetics, therapeutic use)
- Clinical Trials as Topic
(methods)
- Humans
- Migraine Disorders
(diagnosis, drug therapy, metabolism)
- Nausea
(chemically induced)
- Pain
(drug therapy, metabolism)
- Pain Management
(methods)
- Piperidines
(administration & dosage, pharmacokinetics)
- Pyridines
(administration & dosage, pharmacokinetics)
- Solubility
- Tablets
- Treatment Outcome
|